[시장보고서]액체 생검 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제공 형태별, 기술별, 워크플로우별, 검체별, 순환 바이오마커별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

액체 생검 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제공 형태별, 기술별, 워크플로우별, 검체별, 순환 바이오마커별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Offering, By Technology, By Workflow, By Sample, By Circulating Biomarkers, By Application, By End User, By Region and Competition, 2020-2030F

상품코드 : 1878815

리서치사 : TechSci Research

발행일 : 2025년 11월

페이지 정보 : 영문 185 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,681,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 8,165,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,877,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 액체 생검 시장은 2024년에 49억 3,000만 달러로 평가되었으며, 2030년까지 CAGR 12.50%로 성장하여 99억 9,000만 달러에 달할 것으로 예측됩니다.

세계 액체 생검 시장은 주로 혈액 등 체액에 존재하는 순환종양 DNA, 순환종양세포와 같은 유전물질을 검출 및 분석하는 진단 검사에 초점을 맞추고 있습니다. 이 비침습적 방법은 암의 조기 발견, 치료 과정 모니터링, 유전자 돌연변이 확인 등 기존 조직 생검에 비해 많은 이점을 제공합니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	49억 3,000만 달러
시장 규모 : 2030년	99억 9,000만 달러
CAGR : 2025-2030년	12.5%
가장 빠르게 성장하는 부문	차세대 시퀀싱(NGS)
최대 시장	북미

주요 시장 촉진요인

주요 시장 과제

주요 시장 동향

시장 규모 및 예측
- 금액별
시장 점유율과 예측
- 제공 내용별(검사 서비스, 키트, 플랫폼, 기타 소모품)
- 기술별(중합효소 연쇄 반응(PCR), 차세대 시퀀싱(NGS), 기타)
- 워크플로우별(샘플 조제, 라이브러리 조제, 시퀀싱, 데이터 분석·관리)
- 검체별(혈액, 소변, 타액, 기타)
- 순환 바이오마커별(순환종양세포(CTCs), 세포 유리 핵산, 엑소좀 및 세포외소포)
- 용도별(종양학, 비종양학)
- 최종사용자별(임상 검사실, 학술·연구기관, 제약·바이오테크놀러지 기업)
- 지역별
- 기업별(2024)
시장 맵

제6장 북미의 액체 생검 시장 전망

시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제7장 유럽의 액체 생검 시장 전망

시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인

제8장 아시아태평양의 액체 생검 시장 전망

시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 일본
- 한국
- 호주

제9장 중동 및 아프리카의 액체 생검 시장 전망

시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
- 사우디아라비아
- 아랍에미리트
- 남아프리카공화국

제10장 남미의 액체 생검 시장 전망

시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
- 브라질
- 콜롬비아
- 아르헨티나

제11장 시장 역학

성장 촉진요인
과제

제12장 시장 동향과 발전

인수합병
제품 출시
최근 동향

제13장 세계의 액체 생검 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협

제15장 경쟁 구도

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
PerkinElmer Inc.
LungLife AI, Inc.
Illumina, Inc.
QIAGEN NV
NeoGenomics Laboratories, Inc.
Myriad Genetics, Inc.
Bio-Rad Laboratories, Inc.
Guardant Health Inc.
Natera, Inc.
Sysmex Corporation
Abcodia Ltd.
Dxcover Limited

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

KSM

영문 목차

영문목차

The Global Liquid Biopsy Market, valued at USD 4.93 Billion in 2024, is projected to experience a CAGR of 12.50% to reach USD 9.99 Billion by 2030. The global liquid biopsy market focuses on diagnostic tests that detect and analyze genetic material, such as circulating tumor DNA and circulating tumor cells, present in bodily fluids, primarily blood. This non-invasive approach facilitates early cancer detection, treatment monitoring, and identification of genetic mutations, offering advantages over traditional tissue

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 4.93 Billion
Market Size 2030	USD 9.99 Billion
CAGR 2025-2030	12.5%
Fastest Growing Segment	Next Generation Sequencing (NGS)
Largest Market	North America

Key Market Drivers

The global liquid biopsy market's expansion is fundamentally propelled by the escalating worldwide cancer burden. The significant increase in cancer diagnoses necessitates accessible, less invasive diagnostic and monitoring tools. According to the World Health Organization and the International Agency for Research in Cancer, in their February 2024 news release "Global cancer burden growing, amidst mounting need for services", an estimated 20 million new cancer cases occurred worldwide in 2022. This prevalence drives demand for technologies enabling early detection, treatment guidance, and disease monitoring with minimal patient discomfort. Increasing regulatory and clinical validation supports market penetration.

Key Market Challenges

The prevailing concern regarding test accuracy and the absence of universally standardized procedures across various platforms presents a significant impediment to the growth of the global liquid biopsy market. The lack of consistent protocols for assay development, validation, and reporting contributes to variable test performance and potentially inaccurate outcomes. This directly undermines the confidence of healthcare providers in integrating liquid biopsy into routine clinical practice, slowing its broader adoption.

For example, according to a 2024 International Association for the Study of Lung Cancer Global Survey, 26% of surveyed institutions were unaware of any biomarker testing guidelines, while only 54% utilized the comprehensive CAP-IASLC-AMP guidelines. Such discrepancies in guideline awareness and implementation highlight the fragmented landscape of liquid biopsy utilization. This variability complicates comparative analysis across different platforms and laboratories, making it difficult for clinicians to fully trust and rely on the results for critical treatment decisions. Consequently, the market experiences slower expansion as stakeholders exercise caution due to these unresolved issues in standardization and perceived reliability.

Key Market Trends

Multi-analyte and multi-cancer screening development is significantly driving the global liquid biopsy market by enabling the simultaneous detection of various cancer types from a single blood sample. This trend promotes broader, earlier cancer identification, enhancing preventative care and treatment outcomes. In March 2024, the National Institutes of Health launched its Cancer Screening Research Network to evaluate multi-cancer early detection tests, initiating a Vanguard Study enrolling up to 24,000 participants. This highlights national commitment to validating advanced diagnostics. Further demonstrating progress, Exai Bio presented data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, showing its RNA- and AI-based platform achieved 87% overall stage I sensitivity across eight cancer types at 95% specificity in a 3,300 subject study.

Key Market Players

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
PerkinElmer Inc.
LungLife AI, Inc.
Illumina, Inc.
QIAGEN NV
NeoGenomics Laboratories, Inc.
Myriad Genetics, Inc.
Bio-Rad Laboratories, Inc.
Guardant Health Inc.
Natera, Inc.
Sysmex Corporation
Abcodia Ltd.
Dxcover Limited

Report Scope:

In this report, the Global Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Liquid Biopsy Market, By Offering:

Testing Services
Kits
Platform
Other Consumables

Liquid Biopsy Market, By Technology:

Polymerase Chain Reaction (PCR)
Next Generation Sequencing (NGS)
Others

Liquid Biopsy Market, By Workflow:

Sample Preparation
Library Preparation
Sequencing
Data Analysis & Management

Liquid Biopsy Market, By Sample:

Blood
Urine
Saliva
Others

Liquid Biopsy Market, By Circulating Biomarkers:

Circulating Tumor Cells (CTCs)
Cell-free Nucleic Acids
Exosomes & Extracellular Vesicles

Liquid Biopsy Market, By Application:

Oncological
Non-oncological

Liquid Biopsy Market, By End User:

Clinical Laboratories
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies

Liquid Biopsy Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Liquid Biopsy Market.

Available Customizations:

Global Liquid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Liquid Biopsy Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Offering (Testing Services, Kits, Platform, Other Consumables)
- 5.2.2. By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others)
- 5.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
- 5.2.4. By Sample (Blood, Urine, Saliva, Others)
- 5.2.5. By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles)
- 5.2.6. By Application (Oncological, Non-oncological)
- 5.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
- 5.2.8. By Region
- 5.2.9. By Company (2024)
5.3. Market Map

6. North America Liquid Biopsy Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Offering
- 6.2.2. By Technology
- 6.2.3. By Workflow
- 6.2.4. By Sample
- 6.2.5. By Circulating Biomarkers
- 6.2.6. By Application
- 6.2.7. By End User
- 6.2.8. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Liquid Biopsy Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Offering
    - 6.3.1.2.2. By Technology
    - 6.3.1.2.3. By Workflow
    - 6.3.1.2.4. By Sample
    - 6.3.1.2.5. By Circulating Biomarkers
    - 6.3.1.2.6. By Application
    - 6.3.1.2.7. By End User
- 6.3.2. Canada Liquid Biopsy Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Offering
    - 6.3.2.2.2. By Technology
    - 6.3.2.2.3. By Workflow
    - 6.3.2.2.4. By Sample
    - 6.3.2.2.5. By Circulating Biomarkers
    - 6.3.2.2.6. By Application
    - 6.3.2.2.7. By End User
- 6.3.3. Mexico Liquid Biopsy Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Offering
    - 6.3.3.2.2. By Technology
    - 6.3.3.2.3. By Workflow
    - 6.3.3.2.4. By Sample
    - 6.3.3.2.5. By Circulating Biomarkers
    - 6.3.3.2.6. By Application
    - 6.3.3.2.7. By End User

7. Europe Liquid Biopsy Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Offering
- 7.2.2. By Technology
- 7.2.3. By Workflow
- 7.2.4. By Sample
- 7.2.5. By Circulating Biomarkers
- 7.2.6. By Application
- 7.2.7. By End User
- 7.2.8. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Liquid Biopsy Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Offering
    - 7.3.1.2.2. By Technology
    - 7.3.1.2.3. By Workflow
    - 7.3.1.2.4. By Sample
    - 7.3.1.2.5. By Circulating Biomarkers
    - 7.3.1.2.6. By Application
    - 7.3.1.2.7. By End User
- 7.3.2. France Liquid Biopsy Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Offering
    - 7.3.2.2.2. By Technology
    - 7.3.2.2.3. By Workflow
    - 7.3.2.2.4. By Sample
    - 7.3.2.2.5. By Circulating Biomarkers
    - 7.3.2.2.6. By Application
    - 7.3.2.2.7. By End User
- 7.3.3. United Kingdom Liquid Biopsy Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Offering
    - 7.3.3.2.2. By Technology
    - 7.3.3.2.3. By Workflow
    - 7.3.3.2.4. By Sample
    - 7.3.3.2.5. By Circulating Biomarkers
    - 7.3.3.2.6. By Application
    - 7.3.3.2.7. By End User
- 7.3.4. Italy Liquid Biopsy Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Offering
    - 7.3.4.2.2. By Technology
    - 7.3.4.2.3. By Workflow
    - 7.3.4.2.4. By Sample
    - 7.3.4.2.5. By Circulating Biomarkers
    - 7.3.4.2.6. By Application
    - 7.3.4.2.7. By End User
- 7.3.5. Spain Liquid Biopsy Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Offering
    - 7.3.5.2.2. By Technology
    - 7.3.5.2.3. By Workflow
    - 7.3.5.2.4. By Sample
    - 7.3.5.2.5. By Circulating Biomarkers
    - 7.3.5.2.6. By Application
    - 7.3.5.2.7. By End User

8. Asia Pacific Liquid Biopsy Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Offering
- 8.2.2. By Technology
- 8.2.3. By Workflow
- 8.2.4. By Sample
- 8.2.5. By Circulating Biomarkers
- 8.2.6. By Application
- 8.2.7. By End User
- 8.2.8. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Liquid Biopsy Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Offering
    - 8.3.1.2.2. By Technology
    - 8.3.1.2.3. By Workflow
    - 8.3.1.2.4. By Sample
    - 8.3.1.2.5. By Circulating Biomarkers
    - 8.3.1.2.6. By Application
    - 8.3.1.2.7. By End User
- 8.3.2. India Liquid Biopsy Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Offering
    - 8.3.2.2.2. By Technology
    - 8.3.2.2.3. By Workflow
    - 8.3.2.2.4. By Sample
    - 8.3.2.2.5. By Circulating Biomarkers
    - 8.3.2.2.6. By Application
    - 8.3.2.2.7. By End User
- 8.3.3. Japan Liquid Biopsy Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Offering
    - 8.3.3.2.2. By Technology
    - 8.3.3.2.3. By Workflow
    - 8.3.3.2.4. By Sample
    - 8.3.3.2.5. By Circulating Biomarkers
    - 8.3.3.2.6. By Application
    - 8.3.3.2.7. By End User
- 8.3.4. South Korea Liquid Biopsy Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Offering
    - 8.3.4.2.2. By Technology
    - 8.3.4.2.3. By Workflow
    - 8.3.4.2.4. By Sample
    - 8.3.4.2.5. By Circulating Biomarkers
    - 8.3.4.2.6. By Application
    - 8.3.4.2.7. By End User
- 8.3.5. Australia Liquid Biopsy Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Offering
    - 8.3.5.2.2. By Technology
    - 8.3.5.2.3. By Workflow
    - 8.3.5.2.4. By Sample
    - 8.3.5.2.5. By Circulating Biomarkers
    - 8.3.5.2.6. By Application
    - 8.3.5.2.7. By End User

9. Middle East & Africa Liquid Biopsy Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Offering
- 9.2.2. By Technology
- 9.2.3. By Workflow
- 9.2.4. By Sample
- 9.2.5. By Circulating Biomarkers
- 9.2.6. By Application
- 9.2.7. By End User
- 9.2.8. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Liquid Biopsy Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Offering
    - 9.3.1.2.2. By Technology
    - 9.3.1.2.3. By Workflow
    - 9.3.1.2.4. By Sample
    - 9.3.1.2.5. By Circulating Biomarkers
    - 9.3.1.2.6. By Application
    - 9.3.1.2.7. By End User
- 9.3.2. UAE Liquid Biopsy Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Offering
    - 9.3.2.2.2. By Technology
    - 9.3.2.2.3. By Workflow
    - 9.3.2.2.4. By Sample
    - 9.3.2.2.5. By Circulating Biomarkers
    - 9.3.2.2.6. By Application
    - 9.3.2.2.7. By End User
- 9.3.3. South Africa Liquid Biopsy Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Offering
    - 9.3.3.2.2. By Technology
    - 9.3.3.2.3. By Workflow
    - 9.3.3.2.4. By Sample
    - 9.3.3.2.5. By Circulating Biomarkers
    - 9.3.3.2.6. By Application
    - 9.3.3.2.7. By End User

10. South America Liquid Biopsy Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Offering
- 10.2.2. By Technology
- 10.2.3. By Workflow
- 10.2.4. By Sample
- 10.2.5. By Circulating Biomarkers
- 10.2.6. By Application
- 10.2.7. By End User
- 10.2.8. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Liquid Biopsy Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Offering
    - 10.3.1.2.2. By Technology
    - 10.3.1.2.3. By Workflow
    - 10.3.1.2.4. By Sample
    - 10.3.1.2.5. By Circulating Biomarkers
    - 10.3.1.2.6. By Application
    - 10.3.1.2.7. By End User
- 10.3.2. Colombia Liquid Biopsy Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Offering
    - 10.3.2.2.2. By Technology
    - 10.3.2.2.3. By Workflow
    - 10.3.2.2.4. By Sample
    - 10.3.2.2.5. By Circulating Biomarkers
    - 10.3.2.2.6. By Application
    - 10.3.2.2.7. By End User
- 10.3.3. Argentina Liquid Biopsy Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Offering
    - 10.3.3.2.2. By Technology
    - 10.3.3.2.3. By Workflow
    - 10.3.3.2.4. By Sample
    - 10.3.3.2.5. By Circulating Biomarkers
    - 10.3.3.2.6. By Application
    - 10.3.3.2.7. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Liquid Biopsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. F. Hoffmann-La Roche Ltd.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Thermo Fisher Scientific, Inc.
15.3. PerkinElmer Inc.
15.4. LungLife AI, Inc.
15.5. Illumina, Inc.
15.6. QIAGEN NV
15.7. NeoGenomics Laboratories, Inc.
15.8. Myriad Genetics, Inc.
15.9. Bio-Rad Laboratories, Inc.
15.10. Guardant Health Inc.
15.11. Natera, Inc.
15.12. Sysmex Corporation
15.13. Abcodia Ltd.
15.14. Dxcover Limited